MedImmune Cambridge

• Company Profile
• Careers @ Cambridge
• Products
  • Product Pipeline
  • Cambridge-derived Products
  • Licensed Products
  • MEDI-528
• Business Development
• Drug Development
• News And Resources
• Investor Relations
• Contact

Micromet

Micromet was granted a patent licence for the development and commercialisation of their human monoclonal antibody drug candidate MT201 against the epithelial tumour target Ep-CAM. We will receive milestone and royalty payments on product sales arising from the successful development of MT201.

MedImmune Cambridge-derived Clinical Development

Partners	Product	Target	Disease	PreC	PhI	PhII	PhIII	Fld	Mkt
Micromet/Serono	MT201	Ep-CAM	prostate cancer
Micromet/Serono	MT201	Ep-CAM	metastatic breast cancer
Micromet/Serono	MT201	Ep-CAM	relapsed/primary refractory breast cancer

Key to table